Disaggregating the mortality reductions due to cancer screening: model-based estimates from population-based data
暂无分享,去创建一个
[1] H. Welch,et al. Colorectal Cancer on the Decline--Why Screening Can't Explain It All. , 2016, The New England journal of medicine.
[2] D. Oram,et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial , 2016, The Lancet.
[3] Leah Blau,et al. Statistical Models In Epidemiology , 2016 .
[4] J. Hanley,et al. A Conditional Approach to Measure Mortality Reductions Due to Cancer Screening , 2015 .
[5] E. Lynge,et al. Decline in breast cancer mortality: How much is attributable to screening? , 2015, Journal of medical screening.
[6] Douglas K Owens,et al. Models in the Development of Clinical Practice Guidelines , 2014, Annals of Internal Medicine.
[7] Aasma Shaukat,et al. Long-term mortality after screening for colorectal cancer. , 2013, The New England journal of medicine.
[8] J. Hanley,et al. Projecting the yearly mortality reductions due to a cancer screening programme , 2013, Journal of medical screening.
[9] O. Miettinen,et al. Epidemiological Research: An Introduction , 2012, Springer Netherlands.
[10] L. Tabár,et al. Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades. , 2011, Radiology.
[11] J. Hanley. Measuring mortality reductions in cancer screening trials. , 2011, Epidemiologic reviews.
[12] R. Beyth,et al. Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials , 2010, BMJ : British Medical Journal.
[13] J. Hanley,et al. Mortality reductions produced by sustained prostate cancer screening have been underestimated , 2010, Journal of Medical Screening.
[14] Russell P. Harris. Speaking for the evidence: colonoscopy vs computed tomographic colonography. , 2010, Journal of the National Cancer Institute.
[15] B. G. Blijenberg,et al. Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.
[16] Marvin Zelen,et al. Clinical Guidelines Annals of Internal Medicine Effects of Mammography Screening Under Different Screening , 2022 .
[17] M. Law. What Now on Screening for Prostate Cancer? , 2009, Journal of medical screening.
[18] S G Thompson,et al. Screening men for abdominal aortic aneurysm: 10 year mortality and cost effectiveness results from the randomised Multicentre Aneurysm Screening Study , 2009, BMJ : British Medical Journal.
[19] J. Habbema,et al. A novel hypothesis on the sensitivity of the fecal occult blood test , 2009, Cancer.
[20] Amy B. Knudsen,et al. Evaluating Test Strategies for Colorectal Cancer Screening: A Decision Analysis for the U.S. Preventive Services Task Force , 2008, Annals of Internal Medicine.
[21] P. Prorok,et al. Early reporting for cancer screening trials , 2008, Journal of medical screening.
[22] Eric J Feuer,et al. Modeling cancer natural history, epidemiology, and control: reflections on the CISNET breast group experience. , 2006, Journal of the National Cancer Institute. Monographs.
[23] D. Berry,et al. Effect of screening and adjuvant therapy on mortality from breast cancer. , 2006, The New England journal of medicine.
[24] J. Hanley. Analysis of Mortality Data From Cancer Screening Studies: Looking in the Right Window , 2005, Epidemiology.
[25] Elsebeth Lynge,et al. Breast cancer mortality in Copenhagen after introduction of mammography screening: cohort study , 2005, BMJ : British Medical Journal.
[26] G. Friedman,et al. Screening in chronic disease , 2004, Cancer Causes & Control.
[27] John Werth,et al. Mammographic screening: no reliable supporting evidence? , 2002, The Lancet.
[28] P. Gøtzsche,et al. Mammographic screening: no reliable supporting evidence? , 2002, The Lancet.
[29] P C Prorok,et al. Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up. , 2000, Journal of the National Cancer Institute.
[30] M. Gold. Cost-effectiveness in health and medicine , 2016 .